de Groot John F
Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):332-44. doi: 10.1212/01.CON.0000464173.58262.d9.
This article reviews the standard treatment of patients with high-grade glioma primary brain tumors and discusses promising new therapeutic advances.
While surgery and radiation remain critical components of the management of patients with high-grade gliomas, chemotherapy has recently been proven to improve the overall survival of patients with glioblastomas and anaplastic oligodendrogliomas. Molecular markers are complementing clinical prognostic factors and, in some cases, are able to guide treatment decisions. Despite aggressive treatment, high-grade gliomas eventually progress, emphasizing the importance of continued development of novel therapies for the treatment of this deadly disease.
The care of patients with high-grade gliomas is challenging, but the experience is highly rewarding. Rapidly developing technology allows for the use of molecular data for improved classification of high-grade gliomas and is beginning to improve our understanding of the pathogenesis and drivers of this disease. Collaboration among investigators will be critical to effectively validate prognostic biomarkers and identify tumors that might benefit from specific therapies.
本文回顾了高级别胶质瘤（原发性脑肿瘤）患者的标准治疗方法，并讨论了有前景的新治疗进展。
虽然手术和放疗仍然是高级别胶质瘤患者管理的关键组成部分，但最近已证明化疗可提高胶质母细胞瘤和间变性少突胶质细胞瘤患者的总生存率。分子标志物正在补充临床预后因素，在某些情况下，还能够指导治疗决策。尽管进行了积极治疗，高级别胶质瘤最终仍会进展，这凸显了持续开发新疗法以治疗这种致命疾病的重要性。
高级别胶质瘤患者的护理具有挑战性，但经验回报颇丰。快速发展的技术使得能够利用分子数据改进高级别胶质瘤的分类，并开始增进我们对这种疾病的发病机制和驱动因素的理解。研究人员之间的合作对于有效验证预后生物标志物和识别可能从特定疗法中获益的肿瘤至关重要。
